{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:20:28Z","timestamp":1775586028122,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","funder":[{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ebola virus (EBOV) and Marburg virus (MARV) made headlines in the past decade, causing outbreaks of human disease in previously nonendemic yet overlapping areas. While EBOV outbreaks can be mitigated with licensed vaccines and treatments, there is not yet a licensed countermeasure for MARV. Here, we used nonhuman primates (NHPs) previously vaccinated with vesicular stomatitis virus (VSV)\u2013MARV and protected against lethal MARV challenge. After a resting period of 9 months, these NHPs were revaccinated with VSV-EBOV and challenged with EBOV, resulting in 75% survival. Surviving NHPs developed EBOV glycoprotein (GP)-specific antibody titers and no viremia or clinical signs of disease. The single vaccinated NHP succumbing to challenge showed the lowest EBOV GP-specific antibody response after challenge, supporting previous findings with VSV-EBOV that antigen-specific antibodies are critical in mediating protection. This study again demonstrates that VSV\u0394G-based filovirus vaccine can be successfully used in individuals with preexisting VSV vector immunity, highlighting the platform's applicability for consecutive outbreak response.<\/jats:p>","DOI":"10.1093\/infdis\/jiad208","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T20:08:58Z","timestamp":1686254938000},"page":"S671-S676","source":"Crossref","is-referenced-by-count":9,"title":["Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus\u2013Based Filovirus Vaccines in Nonhuman Primates"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-9587","authenticated-orcid":false,"given":"Andrea","family":"Marzi","sequence":"first","affiliation":[{"name":"Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Rocky Mountain Veterinary Branch, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle L","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W","family":"Hanley","sequence":"additional","affiliation":[{"name":"Rocky Mountain Veterinary Branch, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky , Lexington, Kentucky , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023111521042950100_jiad208-B1","author":"Centers for Disease Control and Prevention"},{"key":"2023111521042950100_jiad208-B2","author":"Centers for Disease Control and Prevention"},{"key":"2023111521042950100_jiad208-B3","author":"Centers for Disease Control and Prevention"},{"key":"2023111521042950100_jiad208-B4","author":"Centers for Disease Control and Prevention"},{"key":"2023111521042950100_jiad208-B5","doi-asserted-by":"crossref","first-page":"e1010805","DOI":"10.1371\/journal.ppat.1010805","article-title":"An introduction to the Marburg virus vaccine consortium, MARVAC","volume":"18","author":"Cross","year":"2022","journal-title":"PLoS Pathog"},{"key":"2023111521042950100_jiad208-B6","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"key":"2023111521042950100_jiad208-B7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus\u2013based vaccines against Lassa and Ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2023111521042950100_jiad208-B8","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","article-title":"Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus\u2013based Sudan virus vaccine: a challenge study in macaques","volume":"4","author":"Marzi","year":"2023","journal-title":"Lancet Microbe"},{"key":"2023111521042950100_jiad208-B9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023111521042950100_jiad208-B10","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"9","author":"Marzi","year":"2019","journal-title":"Front Immunol"},{"key":"2023111521042950100_jiad208-B11","doi-asserted-by":"crossref","first-page":"774026","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front Immunol"},{"key":"2023111521042950100_jiad208-B12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"2023111521042950100_jiad208-B13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4269\/ajtmh.18-0937","article-title":"Gamma irradiation as an effective method for inactivation of emerging viral pathogens","volume":"100","author":"Feldmann","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2023111521042950100_jiad208-B14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4269\/ajtmh.19-0076","article-title":"Effect of gamma irradiation on the antibody response measured in human serum from subjects vaccinated with recombinant vesicular stomatitis virus\u2013Zaire Ebola virus envelope glycoprotein vaccine","volume":"101","author":"Grant-Klein","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2023111521042950100_jiad208-B15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/CVI.00170-10","article-title":"Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies","volume":"17","author":"Nakayama","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2023111521042950100_jiad208-B16","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/v14122784","article-title":"Maternal immunization using a protein subunit vaccine mediates passive immunity against Zaire Ebolavirus in a murine model","volume":"14","author":"Williams","year":"2022","journal-title":"Viruses"},{"key":"2023111521042950100_jiad208-B17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023111521042950100_jiad208-B18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci Rep"},{"key":"2023111521042950100_jiad208-B19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"2023111521042950100_jiad208-B20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.chom.2017.10.011","article-title":"Multi-platform \u2018omics analysis of human Ebola virus disease pathogenesis","volume":"22","author":"Eisfeld","year":"2017","journal-title":"Cell Host Microbe"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad208\/50541981\/jiad208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S671\/53451809\/jiad208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S671\/53451809\/jiad208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:11:17Z","timestamp":1700082677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_7\/S671\/7192346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":20,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2023,6,8]]},"published-print":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad208","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,6,8]]}}}